BlackBarn Capital Partners LP holds a focused book of 14 stocks worth $332.4M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened VEECO INSTRUMENTS INC and trimmed ROIVANT SCIENCES LTD. Their largest long position is ROIVANT SCIENCES LTD at 19% of the equity book. They also disclosed $910.7M in put options (a bearish bet), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2010204/holdings"
Use Arkolith to show BlackBarn Capital Partners LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
44% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Roivant Sciences Ltd SHS | $63.3M | 2.29M | 19.0% | ▼−26% Reduced · −799K sh | |
| 2 | Veeco Instrs Inc Del COM | $33.9M | 1.00M | 10.2% | ▲New New position | |
| 3 | Privia Health Group Inc COM | $32.6M | 1.58M | 9.8% | ▲+22% Added · +285K sh | |
| 4 | Diversified Healthcare TR COM SH BEN INT | $32.0M | 4.81M | 9.6% | ▼−26% Reduced · −1.7M sh | |
| 5 | NextEra Energy Inc COM | $31.1M | 335.0K | 9.4% | —Held | |
| 6 | McGraw Hill Inc COM | $28.6M | 2.09M | 8.6% | ▲+49% Added · +688K sh | |
| 7 | Niq Global Intelligence PLC ORDINARY SHARES | $23.6M | 2.07M | 7.1% | ▲+15% Added · +275K sh | |
| 8 | Amneal Pharmaceuticals Inc COM STK CL A | $20.5M | 1.65M | 6.2% | ▲+5.1% Added · +80K sh | |
| 9 | Viking Therapeutics Inc COM | $20.2M | 621.5K | 6.1% | ▲+13% Added · +71K sh | |
| 10 | NXP Semiconductors N V COM | $11.8M | 60.0K | 3.6% | ▲New New position | |
| 11 | Arbutus Biopharma Corp COM | $11.3M | 2.50M | 3.4% | ▲+35% Added · +650K sh | |
| 12 | Global Business Travel Group COM CL A | $11.2M | 2.00M | 3.4% | ▲New New position | |
| 13 | Cogent Communications Hldgs COM NEW | $9.4M | 500.0K | 2.8% | ▼−23% Reduced · −150K sh | |
| 14 | Vivid Seats Inc COM CL A | $3.0M | 500.0K | 0.9% | ▲New New position |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $520.3M | 800K |
| PUT · bearish | ISHARES MSCI BRAZIL ETFEWZ | $201.5M | 5.3M |
| PUT · bearish | RESMED INCRMD | $89.8M | 400K |
| PUT · bearish | AMERICAN AIRLINES GROUP INC | $43.0M | 4.0M |
| PUT · bearish | PALANTIR TECHNOLOGIES INC | $25.6M | 175K |
| PUT · bearish | WARBY PARKER INC-CLASS AWRBY | $21.1M | 1.0M |
| PUT · bearish | COGENT COMM HOLDINGS INC | $9.4M | 500K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 21 | $1.2B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 16 | $1.5B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 20 | $1.4B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 23 | $1.7B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 22 | $1.6B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 17 | $1.8B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 20 | $761.0M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 21 | $1.1B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 23 | $176.9M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 22 | $276.6M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.